FIP22 is a potent and selective IRAK4 PROTAC degrader (HEK293T cells: DC50 = 3.2 nM; THP-1 cells: DC50 = 10.6 nM). FIP22 induces the ubiquitin-proteasome system by forming an IRAK4-FIP22-CRBN ternary complex (EC50 = 12.63 nM), thereby potently blocking IRAK4-mediated NF-κB and MAPK signaling pathways. FIP22 can be used for the study of atopic dermatitis.

PEG3-amide-C2-COOH is a PROTAC linker that can be used in the synthesis of PROTACs, such as BCL6 PROTAC 1.

Aurora kinase ligand-1 (Compound I-4) is an Aurora kinase B (AURKB) PROTAC ligand. Aurora kinase ligand-1 can be conjugated with E3 ligase Ligand and linker to synthesize AURKB PROTAC degrader MS44. MS44 can be used for cancer research.

4-Piperidineethanol-piperidine-Boc is a PROTAC linker can be used in the synthesis of PROTAC BRD4 Degrader-31.

IRAK4 ligand-14 is a ligand for IRAK4. IRAK4 ligand-14 can be used for synthesizing PROTACs such as APH02174.

APH02174 is a highly selective and orally active IRAK4 PROTAC degrader with the DC50 of 4.01 nM in THP-1 cells. APH02174 blocks inflammatory signals by inhibiting IL-6 release. APH02174 can be used for research on inflammatory conditions such as psoriasis vulgaris and rheumatoid arthritis.

E3 Ligase Ligand-linker Conjugate 193 is an E3 ligase ligand-linker conjugate that incorporates the VHL Ligase Ligand and linker. E3 Ligase Ligand-linker Conjugate 193 can be used for synthesis of PROTAC pan-KRAS degrader-1

Alkyne-pyrazine-O-piperidine-(1-methylcyclopropyl) methanol is a PROTAC linker that can be used in the synthesis of PROTACs, such as PROTAC pan-KRAS degrader-1.

(Rac)-EBET-1055 is the racemate of EBET-1055. EBET-1055 is a bromodomain and extra-terminal (BET) PROTAC degrader. EBET-1055 effectively inhibits the growth of pancreatic ductal adenocarcinoma (PDAC). EBET-1055 also simultaneously modulates cancer-associated fibroblast (CAF) activity, upregulating all reporter gene activities in organoid co-cultures.

CH091138 is a potent and selective KRASG12D PROTAC degrader with DC50s of 148.3 nM in HeLa cells and 469.8 nM in AsPC-1 cells. CH091138 selectively degrades exogenous and endogenous KRASG12D but not KRASWT or other KRAS mutants (G12C/G12S/G12V), depending on the VHL-mediated ubiquitin-proteasome system. CH091138 exhibits potent anti-tumor activity and induces cancer cell apoptosis. CH091138 can be used for the studies of pancreatic cancer and colon cancer.

(S,S,S)-VH032-cyclopropane-F is a ligand for E3 ubiquitin ligases. (S,S,S)-VH032-cyclopropane-F can be linked to target protein ligands via a linker to form the PROTAC cis-VZ185.

SMARCA2/4-ligand-6 is a PROTAC target protein ligand (Ligands for Target Protein for PROTACs). SMARCA2/4-ligand-6 can be used for the synthesis of SMARCA2/4-ligand-6.

XIAP ligand-Linker Conjugate 2 is an E3 ligase ligand-linker conjugate that incorporates the XIAP BIR2 ligand XB2M54175348) and linker. XIAP ligand-Linker Conjugate 2 can be used for synthesis of PROTAC GNE-1567.

PDE4 ligand 2 is a CRBN E3 ligase ligand. PDE4 ligand 2 can be used to synthesize PROTAC such as PDE4 degrader-1. PDE4 ligand 2 can be studied in research for autoimmune and anti-inflammatory diseases.

4-[(1E)-2-Nitroethenyl]benzoic acid is an E3 ligase ligand. 4-[(1E)-2-Nitroethenyl]benzoic acid can be used for synthesis of PROTAC BRD4 Degrader-38.

E3 ligase Ligand 67 (Compound 5) is a STUB1/CHIP ligand with a Kd of 8.9  μM for CHIP in fluorescence polarization assay. E3 ligase Ligand 67 is an E3 ligase ligand that can be used for synthesis of PROTACs.

(Methylamino)acetaldehyde is a linker. (Methylamino)acetaldehyde can be used in the synthesis of PROTACs, such as WZH-17-002.

VH032-cyclopropane-F-C4-CHO is an E3 ubiquitinase ligand-linker conjugate. VH032-cyclopropane-F-C4-CHO can be used to synthesize LC-MF-4.

(Rac)-Biotin-PEG3-oxyamine hydrochloride is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.

MD-4251 is an orally active MDM2 PROTAC degrader. MD-4251 potently degrades MDM2 in RS4;11 cells (DC50: 0.2 nM) and actives p53. MD-4251 shows strong antiproliferative activity against acute leukemia cells (wild-type p53) with minimal efficacy in mutant type. MD-4251 induces complete tumor regression in RS4;11 xenograft mice model.

YTHu78 is a KDM5B PROTAC-type degrader. YTHu78 induces KDM5B degradation via the ubiquitin-proteasome system and triggers apoptosis in MV-4-11 and MM.1S cell lines. YTHu78 exhibits significant antiproliferative activity against a variety of hematological cancer cell lines and can be used to study hematological cancers.

FC-14369 is a PROTAC degrader targeting HIV-1 Nef protein with a DC50 value of 160 nM. FC-14369 binds to both Nef and Cereblon E3 ubiquitin ligase via its bifunctional structure, inducing Nef ubiquitination and proteasomal degradation to restore cell-surface CD4 and MHC-I expression and inhibit HIV-1 replication. FC-14369 can be used in research on HIV infection and AIDS.

Thalidomide-bis-NH2-C1-PEG3 is a synthesized E3 ligase ligand-linker conjugate that can be used in the synthesis of PROTACs, such as BETd-246.

FC-14367 is a PROTAC degrader targeting HIV-1 Nef protein. FC-14367 forms a ternary complex by binding Nef and Cereblon E3 ubiquitin ligase, inducing Nef ubiquitination and proteasomal degradation, restoring cell-surface CD4 and MHC-I expression and inhibiting HIV-1 replication. FC-14367 can be used in research on HIV infection and AIDS.

RBN012811 is a selectively PARP14 PROTAC degrader with a DC50 of 5 nM in KYSE-270 cells. RBN012811 significantly decreases IL-10 expression in IL-4 stimulated macrophages.

E3 ligase Ligand 29-azacyclohexane-O-cyclohexane-CO is a synthesized E3 ligase ligand-linker conjugate that can be used to synthesize PROTAC LRRK2 Degrader-3. PROTAC LRRK2 Degrader-3 is a potent LRRK2 PROTAC degrader with anti-neuroinflammatory activity.

YN14 mixture of diastereomers is the diastereomers of YN14). YN14 is a KRASG12C proteolysis targeting chimera (PROTAC). YN14 is highly potent and selective KRASG12C degrader and induces a stable KRASG12C: YN14: VHL ternary complex with low binding free energy (ΔG). YN14 has antiproliferative effects and significantly inhibits KRASG12C-mutant cancer cell growth.